title: CYP2A6 genetic variation and potential consequences.
abstract: Human cytochrome P450 2A6 (CYP2A6) has been shown to have large interindividual and interethnic variability in levels of expression and activity. This is thought to be largely due to genetic polymorphisms. In recent years, 13 genetic variants (CYP2A6*1-*11 and the gene duplication, *1 x 2) of CYP2A6 have been identified and a number of these have been shown to result in altered CYP2A6 enzyme activity. For example, there are alleles which result in variants that are in inactive (e.g. due to a gene deletion), have decreased activity (e.g. altered enzyme structure or transcriptional activity) or have increased activity (e.g. due to gene duplications). The resulting interindividual variation in metabolic activity may affect the metabolism of CYP2A6 substrates including nicotine, cotinine (the major metabolite of nicotine), several tobacco-specific procarcinogens, coumarin and many toxins. The frequencies of the CYP2A6 alleles vary considerably among different ethnic populations, which may partially explain the interethnic variability found in CYP2A6-related metabolic activity (e.g. nicotine metabolism), behaviors (i.e. smoking) and disease (i.e. lung cancer). Investigations of the genetic variation of CYP2A6 and its resulting effects on metabolism and health consequences are still fairly early; this review summarizes what is presently known about CYP2A6, its genetic variants and their clinical consequences.
authors.affiliation: Centre for Addiction and Mental Health, University of Toronto, Toronto M5S 1A8, Canada.
authors.forename: Chun
authors.initials: C
authors.lastname: Xu
authors.forename: Shari
authors.initials: S
authors.lastname: Goodz
authors.forename: Edward M
authors.initials: EM
authors.lastname: Sellers
authors.forename: Rachel F
authors.initials: RF
authors.lastname: Tyndale
mesh_terms: D001189:Aryl Hydrocarbon Hydroxylases / Q000037:antagonists & inhibitors / Q000235:genetics*; D065637:Cytochrome P-450 CYP2A6; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005787:Gene Frequency / Q000235:genetics*; D014644:Genetic Variation; D006801:Humans; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors / Q000235:genetics*; D009369:Neoplasms / Q000201:enzymology / Q000235:genetics; D009538:Nicotine / Q000378:metabolism / Q000627:therapeutic use; D012907:Smoking / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism
chemical_list: D004791:Enzyme Inhibitors; D009538:Nicotine; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C585710:CYP2A6 protein, human; D065637:Cytochrome P-450 CYP2A6